Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma.
about
Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas.Treatment for prolactinomas and hyperprolactinaemia: a lifetime approach.The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial.Dopamine agonists for preventing ovarian hyperstimulation syndrome.Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists.Medical therapy of acromegalyNew avenues in the medical treatment of Cushing's disease: corticotroph tumor targeted therapyRecurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapyCabergoline therapy and the risk of cardiac valve regurgitation in patients with hyperprolactinemia: a meta-analysis from clinical studies.A cross-sectional study of the prevalence of cardiac valvular abnormalities in hyperprolactinemic patients treated with ergot-derived dopamine agonists.Cabergoline therapy for prolactinomas: is valvular heart disease a real safety concern?Cabergoline-induced tricuspid regurgitation: Case report and review of literature.Cabergoline use and risk of fibrosis and insufficiency of cardiac valves. Meta-analysis of observational studies.Risk of cardiac valve regurgitation with dopamine agonist use in Parkinson's disease and hyperprolactinaemia: a multi-country, nested case-control study.The safety of treatments for prolactinomas.The role of combination medical therapy in the treatment of acromegaly.Prospective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia.Screening for valve disease in patients with hyperprolactinaemia disorders prescribed cabergoline: a service evaluation and literature review.Long-term cardiac (valvulopathy) safety of cabergoline in prolactinoma.Pediatric prolactinoma: initial presentation, treatment, and long-term prognosis.No clinically significant valvular regurgitation in long-term cabergoline treatment for prolactinoma.Second attempt to withdraw cabergoline in prolactinomas: a pilot study.A comparison of cabergoline and bromocriptine on the risk of valvular heart disease in patients with prolactinomas.New directions in pharmacological treatment of acromegaly
P2860
Q33579615-013BE76A-18D6-4BD7-98E1-53F3FD08CE69Q33721266-1CE4C96D-8544-4769-A911-DAD98CD8DBA2Q33731989-5C314F49-28EE-4F1B-89C1-262FB5492C78Q34546236-427B99BE-A8E5-4573-BDA9-CFBA6C531707Q35137687-CC5725E6-E433-4771-AFB8-5B3CE2E0F4E3Q35895856-5A2AA3C8-67D0-4728-B5D8-063AEBA9583EQ37049132-750272D4-7F60-4679-9202-328B78E40145Q37257610-360419C8-B47F-4697-97BF-6D07DA50EA9FQ37402278-3C716C72-20A6-4D51-8FDD-75062CDC5E33Q37474118-B96C0A05-3C87-4256-988A-B516023CBAE5Q37656282-CBC7352B-7A20-42EB-9AEA-ADBDAB45F28DQ37897988-7380C90F-32CF-4724-88E4-8895032D6DAEQ38112589-73EF0ABD-AEE5-4777-8005-FEE34279E74DQ38435312-647EB156-3313-4FFC-A575-3EF36B79382AQ38726058-20C97DF3-FC96-4BD5-AF98-37FC67666BABQ38927318-0373F62F-B416-41FB-B2F4-AADE0FA046CAQ39317692-CB6269FD-CC76-4A66-BB66-B8DBA21A740AQ41473311-BA97B4EC-AA46-473A-99E5-E5B2C05284B2Q42111747-2B842F8D-710F-468C-8B52-4F89066BE46CQ47425359-7C513E57-0C87-4F63-BF21-97C25FCEB447Q50971056-10899C4B-FCFD-4F8A-AC8C-5806B76EE16BQ51199076-4DAA0A7C-C549-4DC0-B35C-DD63F2664261Q51425315-FD98CF87-78F0-4B14-9AE9-BBAB019301E4Q58897890-62E0A507-1A15-415A-8401-CA4F987A670A
P2860
Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Aortic valve calcification and ...... nist therapy for prolactinoma.
@en
Aortic valve calcification and ...... nist therapy for prolactinoma.
@nl
type
label
Aortic valve calcification and ...... nist therapy for prolactinoma.
@en
Aortic valve calcification and ...... nist therapy for prolactinoma.
@nl
prefLabel
Aortic valve calcification and ...... nist therapy for prolactinoma.
@en
Aortic valve calcification and ...... nist therapy for prolactinoma.
@nl
P2093
P356
P1476
Aortic valve calcification and ...... nist therapy for prolactinoma.
@en
P2093
Alberto M Pereira
Eduard R Holman
Johannes A Romijn
Johannes W A Smit
Marleen Kars
Richard A Feelders
Victoria Delgado
P304
P356
10.1210/JC.2007-2658
P407
P577
2008-06-17T00:00:00Z